- ICH GCP
- US-Register für klinische Studien
- Klinische Studie NCT03036592
MTNR1B SNP*Food Timing Interaction on Glucose Control (ONTIME-MT)
MTNR1B SNP*Food Timing Interaction on Glucose Control in a Late Eater Mediterranean Population
Studienübersicht
Status
Intervention / Behandlung
Detaillierte Beschreibung
Late-night dinner eating is associated with increased risk for type-2-diabetes. The underlying mechanism is unclear. One explanatory hypothesis is that the concurrence of elevated circulating melatonin and high glucose concentrations (characterizing late-eating) leads to impaired glucose-tolerance. However, to date, no study has tested the influence of physiological melatonin concentrations on glucose tolerance. The discovery of melatonin receptor MTNR1B as a diabetes risk gene provides evidence for a role of physiological levels of melatonin in glucose control.
The aim of the current study is to test the hypothesis that the concurrence of meal timing with elevated endogenous melatonin concentrations results in impaired glucose control and that this effect is stronger in homozygous MTNR1B risk carriers than in non-carriers. To do so we will test glucose tolerance using identical mixed meals under two glucose oral tolerance test (OGTT) conditions: a) delayed OGTT or Late Eating (LE): starting1 hour before their usual bed time, b) advanced OGTT or Early Eating (EE): starting 4 hours before habitual bed time, in a randomized, cross-over study design.
These findings could support a clinical application for the screening of this SNP and the possibility of implementing tailored and cost-effective behavioral interventions to prevent type 2 diabetes in vulnerable populations.
These goals will be achieved through a specific approach:
• Interventional (randomized, cross-over controlled trials) (Aim 1): To study the potential interaction between meal timing (dinner) and genetic variants MTNR1B for glucose tolerance in obese women (n=1000).
Studientyp
Einschreibung (Voraussichtlich)
Phase
- Unzutreffend
Kontakte und Standorte
Studienorte
-
-
-
Murcia, Spanien, 30100
- Rekrutierung
- University of Murcia
-
Kontakt:
- Marta Garaulet, PHD
- Telefonnummer: +34 678996368
- E-Mail: garaulet@um.es
-
Kontakt:
- Jesus Lopez-Minguez
- Telefonnummer: +34 660672851
- E-Mail: jesus.lopez5@um.es
-
-
Teilnahmekriterien
Zulassungskriterien
Studienberechtigtes Alter
Akzeptiert gesunde Freiwillige
Studienberechtigte Geschlechter
Beschreibung
IInclusion Criteria:
- Body Mass Index: > 18.5 o < 40 kg/m2
- Age: between 18 and 65 year of age
- Caucasian
- Day workers
Exclusion Criteria:
- Receiving treatment with thermogenic, lipogenic, or drugs
- Diabetes mellitus, chronic renal failure, hepatic diseases, or cancer diagnosis
- Bulimia diagnosis, prone to binge eating
- Undergoing treatment with Type 2 diabetes mellitus (high blood sugar) medications such as Metformin or other non-Metformin oral anti-diabetic drugs such as sulfonylureas, meglitinides, or glitazones
- Undergoing treatment with Corticosteroids/steroids, Growth hormone, Anticoagulant medicines, or blood thinners, Beta blockers for hypertension, Medications for sleep, Fluvoxamine, Opioids or Amphetamines, Tranquilizers, nonsteroidal anti-inflammatory drugs.
- Pregnant
Studienplan
Wie ist die Studie aufgebaut?
Designdetails
- Hauptzweck: Verhütung
- Zuteilung: Zufällig
- Interventionsmodell: Crossover-Aufgabe
- Maskierung: Keine (Offenes Etikett)
Waffen und Interventionen
Teilnehmergruppe / Arm |
Intervention / Behandlung |
---|---|
Experimental: MTNR1B CC
Test glucose tolerance in homozygous non-carriers (CC) for MTNR1B rs10830963 in Early OGTT and Late OGTT
|
Test glucose tolerance using identical mixed 75 gr of glucose under early condition (4 hours before habitual bedtime)
Test glucose tolerance using identical mixed 75 gr of glucose under late condition (1 hour before habitual bedtime)
|
Experimental: MTNR1B GG
Test glucose tolerance in homozygous (GG) risk allele carriers for MTNR1B rs10830963 in Early OGTT and Late OGTT
|
Test glucose tolerance using identical mixed 75 gr of glucose under early condition (4 hours before habitual bedtime)
Test glucose tolerance using identical mixed 75 gr of glucose under late condition (1 hour before habitual bedtime)
|
Experimental: MTNR1B CG
Test glucose tolerance in heterozygous (CG) risk allele carriers for MTNR1B rs10830963 in Early OGTT and Late OGTT
|
Test glucose tolerance using identical mixed 75 gr of glucose under early condition (4 hours before habitual bedtime)
Test glucose tolerance using identical mixed 75 gr of glucose under late condition (1 hour before habitual bedtime)
|
Was misst die Studie?
Primäre Ergebnismessungen
Ergebnis Maßnahme |
Maßnahmenbeschreibung |
Zeitfenster |
---|---|---|
Area Under the Curve (AUC) glucose
Zeitfenster: between 0-120 minutes, Visit 2 and 3
|
Investigators will measure insulin and glucose levels for 120 minutes at day time and night time visits, and compare them by genotype at selected loci.
|
between 0-120 minutes, Visit 2 and 3
|
Disposition index
Zeitfenster: between 0-120 minutes, Visit 2 and 3
|
Disposition index will be determined by frequently sampled oral glucose tolerance test
|
between 0-120 minutes, Visit 2 and 3
|
Sekundäre Ergebnismessungen
Ergebnis Maßnahme |
Maßnahmenbeschreibung |
Zeitfenster |
---|---|---|
Corrected Insulin Response
Zeitfenster: between 0-120 minutes, Visit 2 and 3
|
Corrected Insulin Response
|
between 0-120 minutes, Visit 2 and 3
|
Insulin Sensitivity Index
Zeitfenster: between 0-120 minutes, Visit 2 and 3
|
Insulin Sensitivity Index
|
between 0-120 minutes, Visit 2 and 3
|
Fasting glucose
Zeitfenster: between 0-120 minutes, Visit 2 and 3
|
Fasting glucose
|
between 0-120 minutes, Visit 2 and 3
|
Fasting insulin
Zeitfenster: 0-120 minutes, Visit 2 and 3
|
Fasting insulin
|
0-120 minutes, Visit 2 and 3
|
Serum Melatonin
Zeitfenster: at baseline and 120 minutes, Visit 2 and 3
|
Serum Melatonin
|
at baseline and 120 minutes, Visit 2 and 3
|
DLMO
Zeitfenster: between 0-5 hours, Visit 3
|
Dim Light Melatonin Onset
|
between 0-5 hours, Visit 3
|
Andere Ergebnismessungen
Ergebnis Maßnahme |
Maßnahmenbeschreibung |
Zeitfenster |
---|---|---|
Chronotyp
Zeitfenster: an der Grundlinie
|
Bewertet mit dem Morningness-Eveningness Questionnaire (MEQ).
|
an der Grundlinie
|
Temperature record
Zeitfenster: total of 1 week between Visit 1 and 2
|
Measured using temperature sensor
|
total of 1 week between Visit 1 and 2
|
Activity record
Zeitfenster: total of 1 week between Visit 1 and 2
|
Measured using Acceleration Data Logger
|
total of 1 week between Visit 1 and 2
|
Light Exposure
Zeitfenster: total of 1 week between Visit 1 and 2
|
Measured using a light sensor
|
total of 1 week between Visit 1 and 2
|
Sleep Duration
Zeitfenster: total of 1 week between Visit 1 and 2
|
Sleep duration will be computed from self-reported
|
total of 1 week between Visit 1 and 2
|
Total Energy Intake
Zeitfenster: total of 1 week between Visit 1 and 2
|
Total energy intake in kcal/day will be computed from 7-day 24-hr dietary recalls
|
total of 1 week between Visit 1 and 2
|
Dietary Composition
Zeitfenster: total of 1 week between Visit 1 and 2
|
Macronutrient and micronutrient intake will be computed from 7-days of self-reported 24-hr dietary recalls
|
total of 1 week between Visit 1 and 2
|
Dietary Intake Timing
Zeitfenster: total of 1 week between Visit 1 and 2
|
Food timing will be self-reported and averaged across 7-days of 24-hr dietary recalls
|
total of 1 week between Visit 1 and 2
|
Physical activity
Zeitfenster: at baseline
|
Assessed using the International Physical Activity Questionnaire (IPAQ)
|
at baseline
|
Emotional eating
Zeitfenster: at baseline
|
Assessed using the Emotional Eating Questionnaire (EEQ)
|
at baseline
|
Sleep quality
Zeitfenster: at baseline
|
Assessed using the Pittsburgh Sleep Quality Index (PSQI)
|
at baseline
|
Insomnia
Zeitfenster: at baseline
|
Assessed using the Insomnia Severity Index (ISI)
|
at baseline
|
Depression
Zeitfenster: at baseline
|
Assessed using the Patient Health Questionnaire (PHQ-9)
|
at baseline
|
Mitarbeiter und Ermittler
Sponsor
Ermittler
- Studienstuhl: Purificación Gomez Abellan, PHD, Universidad de Murcia
Publikationen und hilfreiche Links
Studienaufzeichnungsdaten
Haupttermine studieren
Studienbeginn (Tatsächlich)
Primärer Abschluss (Voraussichtlich)
Studienabschluss (Voraussichtlich)
Studienanmeldedaten
Zuerst eingereicht
Zuerst eingereicht, das die QC-Kriterien erfüllt hat
Zuerst gepostet (Schätzen)
Studienaufzeichnungsaktualisierungen
Letztes Update gepostet (Tatsächlich)
Letztes eingereichtes Update, das die QC-Kriterien erfüllt
Zuletzt verifiziert
Mehr Informationen
Begriffe im Zusammenhang mit dieser Studie
Schlüsselwörter
Andere Studien-ID-Nummern
- 2017ES00001
Plan für individuelle Teilnehmerdaten (IPD)
Planen Sie, individuelle Teilnehmerdaten (IPD) zu teilen?
Arzneimittel- und Geräteinformationen, Studienunterlagen
Studiert ein von der US-amerikanischen FDA reguliertes Arzneimittelprodukt
Studiert ein von der US-amerikanischen FDA reguliertes Geräteprodukt
Diese Informationen wurden ohne Änderungen direkt von der Website clinicaltrials.gov abgerufen. Wenn Sie Ihre Studiendaten ändern, entfernen oder aktualisieren möchten, wenden Sie sich bitte an register@clinicaltrials.gov. Sobald eine Änderung auf clinicaltrials.gov implementiert wird, wird diese automatisch auch auf unserer Website aktualisiert .
Klinische Studien zur Early OGTT
-
Institut de Recherches Cliniques de MontrealVertex Pharmaceuticals Incorporated; Université de MontréalAbgeschlossenMukoviszidose | Diabetes im Zusammenhang mit zystischer FibroseKanada
-
Glostrup University Hospital, CopenhagenAbgeschlossenDiabetes MellitusDänemark
-
Peking University First HospitalAbgeschlossenDiabetes | Schwangerschaftsdiabetes | Makrosomie, fötal
-
Ullevaal University HospitalUnbekanntHerzinfarkt | Entzündung | Typ 2 Diabetes | Eingeschränkt Glukose verträglichNorwegen
-
University of SaskatchewanUniversity of Alberta; Saskatchewan Health Research Foundation; Heart and Stroke... und andere MitarbeiterSuspendiert
-
University of MinnesotaMayo ClinicAbgeschlossenPrädiabetesVereinigte Staaten
-
Saranas, Inc.Cardiovascular Research Foundation, New York; Proxima Clinical Research, Inc.AbgeschlossenKoronare HerzkrankheitVereinigte Staaten
-
Aga Khan UniversityShandong UniversityAnmeldung auf Einladung
-
Bar-Ilan University, IsraelAssociation for Children at RiskUnbekannt
-
Odense University HospitalUniversity of Southern Denmark; Region of Southern Denmark; Municipality of OdenseAbgeschlossenPCO-Syndrom | Schwangerschaftsdiabetes mellitusDänemark